A one month multi-dose study will evaluate the safety and tolerability of 3 intravenous infusions of RSLV-132 in subjects with inactive to mild SLE.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
32
0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
Clinical Research of West Florida
Clearwater, Florida, United States
West Michigan Rheumatology
Grand Rapids, Michigan, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Metroplex Clinical Research
Dallas, Texas, United States
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.